Navigation Links
Trial of new treatment for advanced melanoma shows rapid shrinking of tumors
Date:9/23/2009

Berlin, Germany: Researchers have made significant advances in the treatment of metastatic malignant melanoma one of the most difficult cancers to treat successfully once it has started to spread according to a study to be presented at Europe's largest cancer congress, ECCO 15 ESMO 34 [1], in Berlin on Thursday.

In the phase I extension study, researchers have seen rapid and dramatic shrinking of metastatic tumours in patients treated with a new compound that blocks the activity of the cancer-causing mutation of the BRAF gene, which is implicated in about 50% melanomas and 5% of colorectal cancers. In new results from 31 melanoma patients with the BRAF mutation who were treated with 960mg of PLX4032 twice a day, 64% (14) of the 22 patients who could be evaluated so far met the official criteria for partial response (this involves the diameter of tumours shrinking by at least 30% for at least a month). A further six of the 22 patients also showed a response, but, at the time of the congress presentation, it was too early to say whether the tumours would shrink far enough to meet these criteria.

Dr Paul Chapman, an attending physician on the Melanoma/Sarcoma service at Memorial Sloan-Kettering Cancer Center (New York, USA) and who was one of the leaders of the trial, told a news briefing: "We are very excited about these results. Of the 22 patients we have been able to evaluate so far, 20 have had some objective tumour shrinkage. This is impressive as they all had metastatic disease and most of them had failed several prior therapies. A lot of these patients were pretty sick but many of them had a significant and rapid improvement in the way they function. We've had patients come off oxygen and we've got several patients who have been able to come off narcotic pain medication soon after starting treatment."

The trial is investigating PLX4032 in patients with the BRAF mutation, and results from the first 55 patients were reported at
'/>"/>

Contact: Emma Mason
wordmason@mac.com
44-771-129-6986
ECCO-the European CanCer Organisation
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. IRSF announces funding of first clinical trial with disease-modifying therapy for Rett syndrome
2. World-first swine-flu vaccine trial reveals one dose provides strong immune response
3. This idea doesnt stink: New tech cuts industrial odors, pollutants
4. Resolvyx announces positive data -- Phase 2 trial of resolvin RX-10045 for dry eye syndrome
5. Britains first swine-flu trials under way
6. Extraterrestrial platinum was stirred into the Earth
7. First genetically-engineered malaria vaccine to enter human trials
8. Results from trials of DHA in Alzheimers disease and age-related cognitive decline
9. Funxional successfully completes initial clinical trial of FX125L, an anti-inflammatory drug with a novel mechanism of action
10. Clinical trial shows quadriplegics can operate powered wheelchair with tongue drive system
11. Enzyme doesnt act alone in atrial fibrillation
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... The Parenteral Drug Association (PDA) today confirmed that seven officials ... least seven more will participate in the upcoming 2014 PDA ... Washington D.C. , Dec. 2-4. ... the regulatory agencies in the United States ... to help advance the use of metrics in the regulatory ...
(Date:11/12/2014)... , Nov. 12, 2014 Crossmatch™, a leading ... its U.are.U ® fingerprint readers have been deployed ... Central Mexico . The bakery chain ... eliminate payroll issues caused by employees clocking in for ... U.are.U fingerprint readers, Montparnasse relied on paper timecards and ...
(Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
Breaking Biology News(10 mins):FDA's Janet Woodcock, EMA's Emer Cooke Headline PDA Quality Metrics Conference 2Montparnasse Pasteleria Achieves Time and Attendance Transparency with Crossmatch U.are.U Fingerprint Readers 2
... recently opened pulp mill in Chile has devastated one ... its famed population of black-necked swans, along with most ... Monday. , "What was probably the largest population of ... out in less than a year. It is an ...
... may revolutionize the way birth defects are studied has identified ... birth defects. , Methotrexate (MTX), a popular cancer-fighting drug ... lupus, lasts a long time in the body and causes ... their systems. The study of the drug's effect on fruit ...
... a nanoscale 'compass' inside bacteria orients them to the ... like a compass needle inside the magnetic field. Until ... magnetosomes into a stable chain, against their physical tendency ... and imaging processes, researchers from the Max Planck Institue ...
Cached Biology News:Pulp mill devastates swans' sanctuary in Chile 2Fruit fly research set to revolutionize study of birth defects 2Bacteria which sense the Earth's magnetic field 2Bacteria which sense the Earth's magnetic field 3Bacteria which sense the Earth's magnetic field 4
(Date:11/26/2014)... (PRWEB) November 25, 2014 Global ... by 2019 growing at an estimated CAGR of ... for healthy food products with least ecological impacts, ... mineral fertilizers to boost crop yield more effectively ... products that can improve the return on investments. ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is an in-depth research report on the Global ... report introduces Palmitic Acid, basic information, including definition, ... analysis, and news analysis, etc. , For ... Palmitic Acid market in China and ...
(Date:11/26/2014)... 25, 2014  Roka Bioscience, Inc. (NASDAQ: ROKA ... solutions for the detection of foodborne pathogens, today announced that ... Jaffray  26 th Annual Healthcare Conference on December 2, ... The New York Palace in New York, NY ... concerning the Company, its operations, strategies and prospects may be ...
(Date:11/24/2014)... Belgium , Nov. 24, 2014 ... focused on developing diagnostic tests for cancer and other conditions, ... will be presented at the Science for Business BioWin Day ... Belgium . The data come from VolitionRx,s lung cancer ... Pneumology department of the Centre Hospitalier Universitaire (CHU) de Liege ...
Breaking Biology Technology:2019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 22019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 32019 Biostimulants Market to Grow at a CAGR of 12.5% Says a New Research Report Available at RnRMarketResearch.com 4Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 2Palmitic Acid Industry Global 2014 Analysis & 2020 Forecasts on Market data, Statics, Development Now at ReportsnReports.com 3Roka Bioscience to Present at the Piper Jaffray Healthcare Conference 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 2VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 3VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 4VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 5VolitionRx to Present Positive Data from Pilot Lung Cancer Study at BioWin Day 2014 6
... November 26 Sosei,Group Corporation ("Sosei"; TSE Mothers Index: ... its IP and Know How,relating to the RS(+) isomer ... pharma company, for the treatment and prophylaxis of,malaria. , ... highly efficacious anti-malarial drug that is approved in,its racemic ...
... REGISTRY, the world,s most,authoritative collection of disclosed chemical substance ... Registry Number(R),1073662-18-6 recently was assigned to an azulenobenzofuran derivative. ... http://www.newscom.com/cgi-bin/prnh/20081125/CLTU095 ) , ... The 40 millionth substance was ...
... Sangamo BioSciences,Inc. (Nasdaq: SGMO ) announced ... an update on the progress of Sangamo,s ZFP Therapeutic,development ... at,4:30 pm (ET) on Tuesday, December 2, 2008 at ... York. The company will also update the,financial community ...
Cached Biology Technology:Sosei Announces the Out-licensing of RS(+) Mefloquine to Treague Ltd for the Treatment and Prophylaxis of Malaria 2CAS Registers 40 Millionth Substance in CAS REGISTRY(SM) 2Sangamo BioSciences to Webcast Annual Investor and Analyst Briefing and Presentation at Piper Jaffray Health Care Conference 2
... The BV-10 offers precision beveling ... and 50m. The unique abrasive ... free for greater control of ... be accomplished very rapidly and ...
... Lyophilized. Lyophilized from 2 mM sodium ... human liver. Cathepsin D is a major ... as a 52 kDa proenzyme. Overexpression of ... associated with higher risk of relapse and ...
Rat Hepatocytes (RH) (>3,000,000 cells)...
... Buffer is a concentrated formulation of a ... capillary action technology, as well as for ... with David Brigati M.D., Department of Pathology, ... buffer is recommended for all the rinsing ...
Biology Products: